The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced “on par” with Cerezyme, which goes for around $300,000 a year in the US.
Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma’s Eric Pauwels, who’s launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports
BI drug gets priority review
July 2, 2014
5:07 pm
Boehringer Ingelheim’s experimental idiopathic pulmonary fibrosis treatment nintedanib is also an orphan drug.